Filing Flows › Citius Oncology (CTOR) › Q1 FY26
Citius Oncology (CTOR) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 13, 2026
Citius Oncology (CTOR) reported revenue of $3.9M for the first quarter fiscal 2026 (Q1 FY26). Operating margin was -133.2%, net loss $5.5M (140.3% of revenue).
Citius Oncology, Q1 FY26: revenue $3.9M, operating margin -133.2%, net loss $5.5M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.9M | — | — |
| Operating profit | −$5.3M | — | — |
| Net earnings | −$5.5M | — | — |
| Operating cash flow | −$7.4M | — | — |
What changed
Revenue was $3.9M in Q1 FY26.
Gross margin was 80.0%. Operating costs exceeded revenue by $5.3M, an operating margin of -133.2%. The quarter ended with a net loss of $5.5M.
Operating cash flow was −$7.4M. Non-cash charges added back $4.0M of share-based compensation. Working capital and other items used $5.8M.
Questions
What was Citius Oncology's revenue in the first quarter fiscal 2026?
Citius Oncology (CTOR) reported revenue of $3.9M for the first quarter fiscal 2026 (Q1 FY26).
Was Citius Oncology profitable in the first quarter fiscal 2026?
Operating loss was $5.3M (-133.2% of revenue) and net loss $5.5M.
Source: Citius Oncology 10-Q on SEC EDGAR.